Mahdy 2013.
| Study characteristics | ||
| Methods |
Study design: parallel‐group RCT Setting: single center trial in Egypt Number randomized: 40 participants Unit of analysis: participant (one study eye per individual) Maximum planned (or stated) length of follow‐up: 18 months Number not included in final analysis: all participants included at 18 months |
|
| Participants |
Number of men: 12 in the intervention group and 11 in the comparator group Number of women: 8 in the intervention group and 9 in the comparator group Mean age: 55 years in the intervention group and 56 years in the comparator group Mean IOP at baseline: 38 mmHg in the intervention group and 39 mmHg in the comparator group Inclusion criteria: uncontrolled NVG using maximum tolerated glaucoma medication, with evident iris neovascularization and active retinal pathology; no previous PRP Exclusion criteria: no light perception; unwilling or unable to provide written informed consent; uncontrolled hypertension, renal disease, or a history of thromboembolic events, including myocardial infarction, cerebral insult |
|
| Interventions |
Intervention (N = 20): 0.05 mL intravitreal bevacizumab (1.25 mg) and PRP; Ahmed glaucoma valve implant two weeks after injection Comparator (N = 20): PRP with Ahmed glaucoma valve implant |
|
| Outcomes |
From study methods "At each visit, complete ophthalmic evaluation included best corrected visual acuity, corneal appearance, iris neovascularization, anterior chamber depth, IOP measurements, bleb appearance, and fundus examination". |
|
| Notes |
Trial registration: not reported Study dates: not reported |
|
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Unclear risk of bias – insufficient information to permit judgment of low risk or high risk of bias |
| Allocation concealment (selection bias) | Unclear risk | Unclear risk of bias – insufficient information to permit judgment of low risk or high risk of bias |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Unclear risk of bias – insufficient information to permit judgment of low risk or high risk of bias |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Unclear risk of bias – insufficient information to permit judgment of low risk or high risk of bias |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Unclear risk of bias – insufficient information to permit judgment of low risk or high risk of bias |
| Selective reporting (reporting bias) | Unclear risk | Unclear risk of bias – insufficient information to permit judgment of low risk or high risk of bias |
| Other bias | Unclear risk | Unclear risk of bias ‐ insufficient information to permit judgment of low risk or high risk of bias; study was not registered in a clinical trials registry; it declared "no conflict of interest"; there was no information about source of funding. |
IOP: intraocular pressure IVB: intravitreal bevacizumab IVT‐AFL: intravitreal aflibercept mmHg: millimeters of mercury NVA: neovascularization of the angle NVG: neovascular glaucoma NVI: neovascularization of the iris PDGF‐C: platelet‐derived growth factor C PRP: panretinal photocoagulation RCT: randomized controlled trial RNFL: retinal nerve fiber layer VEGF: vascular endothelial growth factor